Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival

Kidney International

Volumn 70, Issue 8, 2006, Pages 1503-1509

  Williams, M E ^a   Lacson Jr , E ^b   Teng, M ^b   Ofsthun, N ^b   Lazarus, J M ^b  

^a JOSLIN DIABETES CENTER   (United States)

^b FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

Author keywords

Diabetes; ESRD; Hemodialysis; Hemoglobin A1c; Hyperglycemia; Survival

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; POPULATION RISK; PRIORITY JOURNAL; SURVIVAL; SURVIVAL RATE; UNITED STATES;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; SURVIVAL RATE; UNITED STATES;

EID: 33749534536     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001789     Document Type: Article

References (57)

1. System USRD: USRDS 2005 Annual Data Report. Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases: Bethesda, MD 2005.
2. Koro CE, Bowlin SJ, Bourgeois N et al. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004; 27: 17-20.
3. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002; 45: S23-28.
4. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342.
5. American Diabetes Association. Tests of glycemia in diabetes (position statement). Diabetes Care 2004; 27: S91-S93.
6. Wei M, Gaskill SP, Haffner SM et al. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998; 21: 1167-1172.
7. Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583.
8. Kuusisto J, Mykkanen L, Pyorala K et al. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-967.
9. Andersson DK, Svardsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 1995; 18: 1534-1543.
10. Engelgau MM, Geiss LS, Saaddine JB et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140: 945-950.
11. Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-431.
12. Menon V, Greene T, Pereira AA et al. Glycosylated hemoglobin and mortality in patients with nondiabetic chronic kidney disease. J Am Soc Nephrol 2005; 16: 3411-3417.
13. Selvin E, Coresh J, Golden SH et al. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005; 165: 1910-1916.
14. Manske CL. Hyperglycemia and intensive glycemic control in diabetic patients with chronic renal disease. Am J Kidney Dis 1998; 32: S157-S171.
15. Tzamaloukas AH, Murata GH, Zager PG et al. The relationship between glycemic control and morbidity and mortality for diabetics on dialysis. Asaio J 1993; 39: 880-885.
16. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314: 1512-1515.
17. Malmberg K, Norhammar A, Wedel H et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: longterm results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999; 99: 2626-2632.
18. Ceriello A, Hanefeld M, Leiter L et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004; 164: 2090-2095.
19. Joy MS, Cefalu WT, Hogan SL et al. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002; 39: 297-307.
20. American Diabetes Association. Standards of medical care in diabetes (position statement). Diabetes Care 2004; 27: S15-S35.
21. Akmal M. Hemodialysis in diabetic patients. Am J Kidney Dis 2001; 38: S195-199.
22. Morioka T, Emoto M, Tabata T et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001; 24: 909-913.
23. Goldstein DE, Little RR, Lorenz RA et al. Tests of glycemia in diabetes. Diabetes Care 2004; 27: 1761-1773.
24. Larsen ML, Horder M, Mogensen EF. Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. N Engl J Med 1990; 323: 1021-1025.
25. Dunn PJ, Cole RA, Soeldner JS et al. Reproducibility of hemoglobin Alc and sensitivity to various degrees of glucose intolerance. Ann Intern Med 1979; 91: 390-396.
26. Meigs JB, Nathan DM, Cupples LA et al. Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. J Clin Epidemiol 1996; 49: 411-417.
27. American Diabetes Association. Standards of medical care in diabetes (position statement). Diabetes Care 2005; 28: S4-S36.
28. American Diabetes Association. Clinical practice recommendations. Diabetes Care 2006; 29: S3.
29. Collins AJ, Li S, Gilbertson DT et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 2003: S24-S31.
30. Morgan L, Marenah CB, Jeffcoate WJ et al. Glycated proteins as indices of glycaemic control in diabetic patients with chronic renal failure. Diabet Med 1996; 13: 514-519.
31. Stettler C, Mueller B, Diem P. What you always wanted to know about HbA1c. Schweiz Med Wochenschr 2000; 130: 993-1005.
32. Nakao T, Matsumoto H, Okada T et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998; 37: 826-830.
33. Williams ME LE, Lazarus JM et al. Glycohemoglobin levels and the subsequent impact on mortality risk in diabetic hemodialysis (HD) patients. J Am Soc Nephrol 2005; 16: 723A-724A.
34. Williams ME LE, Lazarus JM et al. Differences between Type 1 and Type 2 DM patients on hemodialysis. J Am Soc Nephrol 2005; 16: 723A.
35. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26(Suppl 1): S5-S20.
36. Feinglos MN, Bethel MA. Emerging care for type 2 diabetes: using insulin to reach lower glycemic goals. Cleveland Clin J Med 2005; 72: 791-799.
37. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-1298.
38. Flauto RP, Leon JB, Sehgal AR. The provision and outcomes of diabetic care of hemodialysis patients. Am J Kidney Dis 2003; 41: 125-131.
39. Rohlfing CL, Wiedmeyer HM, Little RR et al. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275-278.
40. Tuohy KWM. Management of the diabetic ESRD Patient: Dialysis and transplantation. Elsevier: Philadelphia, 2005.
41. Little RR, Tennill AL, Rohlfing C et al. Can glycohemoglobin be used to assess glycemic control in patients with chronic renal failure? Clin Chem 2002; 48: 784-786.
42. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992; 51: 76-89.
43. www.cmms.hhs.gov. US Department of Health and Human Services.
44. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 2000; 13: 4-8.
45. Ifudu O, Dulin AL, Friedman EA. Interdialytic weight gain correlates with glycosylated hemoglobin in diabetic hemodialysis patients. Am J Kidney Dis 1994; 23: 686-691.
46. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
47. Khaw KT, Wareham N, Luben R et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322: 15-18.
48. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35: S117-131.
49. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
50. Ichikawa H, Nagake Y, Takahashi M et al. What is the best index of glycemic control in patients with diabetes mellitus on hemodialysis? Nippon Jinzo Gakkai Shi 1996; 38: 305-308.
51. Ansari A, Thomas S, Goldsmith D. Assessing glycemic control in patients with diabetes and end-stage renal failure. Am J Kidney Dis 2003; 41: 523-531.
52. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482.
53. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
54. Pogach LM, Brietzke SA, Cowan Jr CL et al. Development of evidence-based clinical practice guidelines for diabetes: the Department of Veterans Affairs/Department of Defense guidelines initiative. Diabetes Care 2004; 27(Suppl 2): B82-B89.
55. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
56. Loipl J, Schmekal B, Biesenbach G. Long-term impact of chronic hemodialysis on glycemic control and serum lipids in insulin-treated type 2-diabetic patients. Renal Fail 2005; 27: 305-308.
57. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999; 354: 617-621.